Randomized Phase III Trial of Atezolizumab + Bevacizumab  The combination therapy proved efficacious, progression-free survival by PD-L1 group

Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group

179 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group at the 2018 ASCO.
Up Next Autoplay